The company is not selling any shares of common stock under this prospectus and will not receive any of the proceeds from the sale or other disposition of common stock by the selling stockholders.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Technologies: Promising Outlook with Yutrepia Launch and Legal Wins Support Buy Rating
- Buy Rating for Liquidia Technologies: Anticipated FDA Approval and Market Expansion Drive Positive Outlook
- United Therapeutics price target lowered to $314 from $328 at BofA
- Options Volatility and Implied Earnings Moves Today, March 19, 2025
- Liquidia targets final FDA approval of Yutrepia after May 23
Questions or Comments about the article? Write to editor@tipranks.com